Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. (Q48391405)

11 February 2018

title

Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. (English)

1 reference

11 February 2018

0 references

0 references

1 reference

6

Shiwei Duan

1 reference

11 February 2018

author name string

Qinghe Xing

1

1 reference

11 February 2018

Rui Gao

2

1 reference

11 February 2018

Huafang Li

3

1 reference

11 February 2018

Guoyin Feng

4

1 reference

11 February 2018

Mingqing Xu

5

1 reference

11 February 2018

Junwei Meng

7

1 reference

11 February 2018

Aiping Zhang

8

1 reference

11 February 2018

Shengying Qin

9

1 reference

11 February 2018

Lin He

10

1 reference

11 February 2018

publication date

1 October 2006

1 reference

11 February 2018

published in

Pharmacogenomics

1 reference

11 February 2018

volume

7

1 reference

11 February 2018

issue

7

1 reference

11 February 2018

page(s)

987-993

1 reference

11 February 2018

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Localization of multidrug resistance-associated DNA sequences to human chromosome 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

A new structural model for P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.987

21 January 2018

Identifiers

DOI

10.2217/14622416.7.7.987

1 reference

11 February 2018

PubMed ID

17054409

1 reference

11 February 2018